Graded and cross-reactive JAK-receptor interactions broaden the one-receptor, one-JAK rule
This study challenges the traditional "one-receptor, one-JAK" model by demonstrating through biophysical and cellular assays that JAK-receptor interactions are cross-reactive, exhibit a wide range of binding affinities, and function in a permissive, graded manner rather than being strictly exclusive and constitutive.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body relies on a vast, silent communication network to coordinate its defenses, manage growth, and maintain balance. This network operates through signaling proteins called cytokines, which act like messengers traveling between cells. When a cytokine arrives at a cell, it docks onto a specific receptor on the cell's surface. These receptors, however, are not active on their own; they are like locked doors that require a specific key to open. That key is a family of enzymes known as Janus kinases, or JAKs. For decades, scientists have operated under a strict rule of engagement: each receptor is paired with exactly one dedicated JAK enzyme, and they are permanently attached to one another, waiting for the signal to arrive. This "one receptor, one JAK" model suggested a rigid, pre-assembled system where the connection was always strong and exclusive, ensuring that the right message always reached the right destination.
This long-held view, however, has now been challenged by a new study that looked directly at the physical strength and flexibility of these connections. Researchers at the University of Chicago set out to test whether these partnerships were as permanent and exclusive as textbooks claimed. They focused on two specific JAK enzymes, JAK1 and TYK2, and tested them against a panel of thirty-two different receptor parts. Instead of assuming the connections were fixed, they measured how tightly the enzymes actually stuck to the receptors. The results revealed a much more fluid and adaptable system. The researchers found that the strength of the bond between a receptor and its enzyme varied wildly, ranging from very tight connections to very loose ones. More surprisingly, they discovered that many receptors were not picky at all; they could bind to multiple different enzymes with significant strength, breaking the rule of exclusive pairing.
The team began by examining the genetic blueprints of the receptor parts to see if they followed a predictable pattern. They aligned the sequences of the regions where the enzymes attach, looking for common features that might explain why a specific enzyme would choose one receptor over another. While they found some shared structural elements, the overall sequences were surprisingly diverse, even among receptors that were thought to work with the same enzyme. This diversity suggested that the system might be more flexible than previously imagined. To test this, the researchers created a screening system using tiny magnetic beads coated with the receptor parts. They then introduced the JAK enzymes to see which ones would stick. The results were immediate and unexpected. Many receptors that were thought to bind only to one specific enzyme showed strong attraction to others. For instance, a receptor part known as GM-CSFRα, which was believed to work exclusively with JAK2, was found to bind just as strongly to JAK1 and TYK2. Similarly, a part of the interleukin-2 receptor, called IL2Rβ, which was assigned to JAK1, actually held onto TYK2 much more tightly than it held onto its supposed partner.
To confirm these initial findings, the researchers moved to a more precise method to measure the exact strength of these bonds. They used a technique that tracks how molecules move in response to heat, allowing them to calculate the dissociation constant, a number that describes how easily two molecules separate. The data showed a wide spectrum of binding strengths. Some pairs, like the connection between TYK2 and the IFNαR1 receptor, were very tight, with a dissociation constant of 48 nanomolar. Others were much weaker, with constants in the tens of micromolar range, meaning they would fall apart easily unless held together by other forces. Crucially, the study showed that the "canonical" or textbook pairings were not always the strongest. In several cases, the non-canonical partners bound with equal or greater affinity. For example, the GM-CSFRα receptor bound to JAK1 with a strength of 758 nanomolar and to TYK2 with a strength of 1.34 micromolar, proving that these alternative connections were physically capable of forming stable complexes.
The most critical question remained: do these physical bonds actually work inside a living cell? A strong connection in a test tube does not guarantee it can drive a biological signal. To answer this, the researchers turned to human cells and used a combination of drugs to block specific enzymes, effectively turning them off one by one. They wanted to see if a receptor could still send a message if its primary enzyme was disabled, relying instead on one of the alternative partners they had identified. They focused on the GM-CSF receptor, which is canonically paired with JAK2. When they blocked JAK2, JAK3, and TYK2, leaving only JAK1 active, the cells were still able to respond to the GM-CSF signal. In fact, the cells retained about 65% of their normal signaling strength. This was a striking result, as the canonical partner, JAK2, when left alone with all others blocked, only managed about 23% of the signal. This demonstrated that the non-canonical pairing was not just a physical curiosity but a functional reality that could sustain the cell's communication even when the primary system was compromised.
These findings suggest that the immune system's signaling network is not a rigid circuit board with fixed wires, but rather a dynamic landscape where connections are graded and competitive. The idea that every receptor is permanently and exclusively occupied by a single enzyme appears to be an oversimplification. Instead, the system seems to rely on a balance of affinities, where the strength of the bond and the abundance of the enzymes determine which partnership forms at any given moment. This flexibility has profound implications for how we understand diseases and treat them. Many modern drugs, known as JAK inhibitors, are designed to block specific enzymes to treat conditions like rheumatoid arthritis or blood disorders. If the system is more permissive than assumed, a drug that blocks one enzyme might not fully stop the signal if another enzyme can step in and take its place. The study indicates that the body has a latent reserve of alternative pathways that can be activated when the primary route is blocked, which could explain why some treatments are only partially effective.
The researchers were careful to note the limits of their work. They tested only two of the four known JAK enzymes, JAK1 and TYK2, because the others were difficult to produce in the lab for these specific experiments. They also studied isolated parts of the receptors and enzymes outside of the cell membrane, which means they did not capture the full complexity of how these molecules behave in their natural environment. Despite these limitations, the data provides a clear picture of the underlying physics. The interactions are not uniformly high-affinity, nor are they exclusive. The "one receptor, one JAK" rule is better understood as a general tendency rather than a strict law. The system is tuned to be adaptable, allowing for a range of signaling outcomes depending on the specific cellular context and the availability of different enzymes. This new perspective shifts the focus from a static map of connections to a dynamic view of competition and cooperation, offering a more accurate foundation for understanding how cells communicate and how we might intervene when that communication goes wrong.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.